Document is current
Any future updates will be listed below
-
Authors
Zhou, Chen
Huang, Hui
Wang, Yunyi
Sendinc, Erdem
Shi, Yang
-
Funding
Funding for this research was provided by:
Ludwig Institute for Cancer Research
- License Information
-
More Information
Article History
Received: 12 July 2022
Accepted: 13 September 2022
First Online: 18 October 2022
Conflict of interest
: Y.S. is a co-founder and member of the Scientific Advisory Board of K36 Therapeutics. Y.S. is also a member of the Scientific Advisory Board of EPICRISPR BIOTECHNOLOGIES, INC and a member of the MD Anderson External Advisory Board. Y.S. is a scientific consultant for CBio-X Holdings, Inc., and holds equity in Imago Biosciences, Active Motif and K36 Therapeutics. The remaining authors declare no competing interests.
